Table 4

Clinical data for ankylosing spondylitis patients in stratified by fecal calprotectin positivity

Fecal calprotectin cutoff 50 μg/g

Fecal calprotectin positive (n = 16)

Fecal calprotectin negative (n = 23)

P value

NSAID use

6 (38%)

10 (43%)

0.75

Enbrel use

9 (56%)

8 (35%)

0.20

Patients waking up at night for bowel movement

3 (19%)

3 (13%)

0.67

BASDAI score

3.0 (0.1 to 7.75)

1.8 (0.03 to 7.66)

0.16

BASRI score

6.0 (2 to 13.5)

5.0 (2 to 11)

0.64

BASFI score

41.6 (0.4 to 92.5)

17.1 (0 to 72.1)

0.09

Erythrocyte sedimentation rate

8.5 (0 to 62)

17 (2 to 64)

0.75

C-reactive protein

0.44 (0.03 to 5.7)

0.57 (0.02 to 4.84)

0.58

Patients with history of uveitis

7 (44%)

10 (43%)

1.0

Patients with history of peripheral arthritis in the knee

4 (25%)

5 (22%)

1.0

Patients with history of peripheral arthritis in the ankle

5 (31%)

4 (17%)

0.44

Data presented as median (range) or number (percentage). BASDAI, Bath ankylosing spondylitis disease activity index; BASFI, Bath ankylosing spondylitis functional index; BASRI, Bath ankylosing spondylitis radiology index.

Matzkies et al. Arthritis Research & Therapy 2012 14:R261   doi:10.1186/ar4106